Alkermes plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALKS Nasdaq 2836 www.alkermes.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alkermes plc

Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Jan 15th, 2026 9:16 am
Are Medical Stocks Lagging Alkermes (ALKS) This Year? - Jan 15th, 2026 7:40 am
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Jan 14th, 2026 10:10 am
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific - Jan 14th, 2026 8:18 am
Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close - Jan 13th, 2026 4:23 pm
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes - Jan 12th, 2026 2:05 pm
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug - Jan 7th, 2026 9:45 am
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data - Jan 7th, 2026 12:09 am
Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Jan 6th, 2026 7:14 pm
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 - Jan 6th, 2026 5:00 am
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 30th, 2025 2:00 pm
Why Analysts are Rating Alkermes (ALKS) a Buy - Dec 22nd, 2025 4:50 am
Are Investors Undervaluing Alkermes (ALKS) Right Now? - Dec 8th, 2025 7:40 am
How Recent Deal Developments Are Reshaping The Avadel Pharmaceuticals Investment Story - Dec 5th, 2025 5:20 pm
Announcement relating to despatch of Rule 15 proposal - Dec 5th, 2025 2:01 pm
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Dec 3rd, 2025 2:47 pm
Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Dec 2nd, 2025 4:13 am
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting - Dec 1st, 2025 2:05 pm
Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? - Nov 27th, 2025 9:30 am
Avadel (AVDL) Drops 6.7% on Lack of Leads - Nov 27th, 2025 7:22 am